|
1) The Committee of Brain Tumor Registry of Japan. Report of Brain Tumor Registry of Japan (1969-1996). Neurol Med Chir (Tokyo). 2003; Suppl 43
|
|
|
|
|
2) Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilmʼs tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004; 101: 13885-90
|
|
|
|
|
3) Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: A National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009; 15: 5323-37
|
|
|
|
|
|
4) Izumoto S, Hashimoto N, Yoshimine T, et al. Phase II clinical trial of WT1 (Wilms tumor gene) peptide vaccination for patients with recurrent glioblastoma. J Neurosurg. 2008; 108: 963-71
|
|
|
|
|
|
5) Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilmʼs tumor gene (WT1) product. Immunogenetics. 2000; 51: 99-107
|
|
|
|
|
|
6) Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(＋) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000; 95: 2198-203
|
|
|
|
|
|
7) Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(＋) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000; 95: 286-93
|
|
|
|
|
|
8) Li Z, Oka Y, Tsuboi A, et al. Identification of a WT1 protein-derived peptide, WT1187 as an HLA-A＊0206-restricted, WT1-specific CTL epitope. Microbiol Immunol. 2008; 52: 551-8
|
|
|
|
|
9) Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilmʼs tumor gene WT1 product. J Immunol. 2000; 164: 1873-80
|
|
|
|
|
|
10) Oka Y, Tsuboi A, Murakami M, et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelo-dysplastic syndrome (MDS) or MDS with myelo-fibrosis. Int J Hematol. 2003; 78: 56-61
|
|
|
|
|
|
11) Tsuboi A, Oka Y, Nakajima H, et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol. 2007; 86: 414-7
|
|
|
|
|
|
12) Iiyama T, Udaka K, Takeda S, et al. WT1 (Wilmʼs Tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol. 2007; 51: 519-30
|
|
|
|
|
|
13) Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205-16
|
|
|
|
|
|
14) Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17: 2572-8
|
|
|
|
|
|
15) Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2006; 352: 987-96
|
|
|
|
|
|
16) Chiba Y, Hashimoto N, Tsuboi A, et al. Prog-nostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients. Brain Tumor Pathol, 2010; 27: 29-34
|
|
|
|
|
|
17) Fujiki F, Oka Y, Tsuboi A, et al. Identification and characterization of a WT1 (Wilms tumor gene) orotein-derived HLA-DRB1＊0405-restricted 16-mer helper peptide that promotes the induc-tion and activation of WT1-specific cytotoxic T lymphocytes. J Immunother. 2007; 30: 282-93
|
|
|
|
|
|
18) Chiba Y, Hashimoto N, Tsuboi A, et al. Effects of concomitant temozolomide and radiation thera-pies on WT1-specific T cells in malignant glioma. JPN J Clin Oncol. 2010; 40: 395-408
|
|
|
|
|